Literature DB >> 10100312

Influence of crystal habit on trimethoprim suspension formulation.

A K Tiwary1, G M Panpalia.   

Abstract

PURPOSE: The role of crystal habit in influencing the physical stability and pharmacokinetics of trimethoprim suspensions was examined.
METHODS: Different habits for trimethoprim (TMP) were obtained by recrystallizing the commercial sample (PD) utilizing solvent-change precipitation method. Four distinct habits (microscopic observation) belonging to the same polymorphic state (DSC studies) were selected for studies. Preformulation and formulation studies were carried out on suspension dosage forms containing these crystals. The freshly prepared suspensions were also evaluated for their pharmacokinetic behaviour on healthy human volunteers using a cross over study.
RESULTS: Variation of crystallization conditions produces different habits of TMP. Among the different crystal habits exhibiting same polymorphic state, the most anisometric crystal showed best physical stability in terms of sedimentation volume and redispersibility. However, habit did not significantly affect the extent of TMP excreted in urine.
CONCLUSIONS: Modification of surface morphology without significantly altering the polymorphic state can be utilized for improving physical stability of TMP suspensions. However, the pharmacokinetic profile remains unaltered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100312     DOI: 10.1023/a:1018832526093

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  The influence of crystal form on the radial stress transmission characteristics of pharmaceutical materials.

Authors:  M P Summers; R P Enever; J E Carless
Journal:  J Pharm Pharmacol       Date:  1976-02       Impact factor: 3.765

2.  Characterization of habits and crystalline modification of solids and their pharmaceutical applications.

Authors:  J K Haleblian
Journal:  J Pharm Sci       Date:  1975-08       Impact factor: 3.534

3.  X-ray and crystallographic applications in pharmaceutical research. III. Crystal habit quantitation.

Authors:  J W SHELL
Journal:  J Pharm Sci       Date:  1963-01       Impact factor: 3.534

4.  Electrophoretic study of nitrofurantoin in aqueous suspensions. Effect of the addition of a polymeric thickener.

Authors:  V Gallardo; A Delgado; A Parera; J Salcedo
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

5.  Human pharmacokinetics of two crystalline and galenic forms of diflunisal, a new analgesic.

Authors:  A Dresse; M A Gérard; A Lays; K F Tempero; L Verhaest
Journal:  Pharm Acta Helv       Date:  1978

6.  The compression properties of lactose.

Authors:  O Alpar; J A Hersey; E Shotton
Journal:  J Pharm Pharmacol       Date:  1970-12       Impact factor: 3.765

7.  Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids.

Authors:  S A Kaplan; R E Weinfeld; T L Lee
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

Review 8.  Pharmaceutical solids: a strategic approach to regulatory considerations.

Authors:  S Byrn; R Pfeiffer; M Ganey; C Hoiberg; G Poochikian
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

9.  The effect of particle shape and crystal habit on properties of sodium chloride.

Authors:  E Shotton; B A Obiorah
Journal:  J Pharm Pharmacol       Date:  1973-12       Impact factor: 3.765

10.  Physical characterization of erythromycin: anhydrate, monohydrate, and dihydrate crystalline solids.

Authors:  P V Allen; P D Rahn; A C Sarapu; A J Vanderwielen
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

View more
  1 in total

1.  The crystal structure and physicochemical characteristics of 2-hydroxy-N-[3(5)-pyrazolyl]-1,4-naphthoquinone-4-imine, a new antitrypanosomal compound.

Authors:  Norma R Sperandeo; Alicia Karlsson; Silvia Cuffini; Silvina Pagola; Peter W Stephens
Journal:  AAPS PharmSciTech       Date:  2005-12-27       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.